First AD

Second AD

The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.

Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

Video content above is prompted by the following:

What are some key takeaways you wish to offer community oncologists?

Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: Optimizing Care for Relapsed / Refractory Multiple Myeloma: Translating Evidence to Clinical Practice

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

Winship Cancer Institute of Emory University

Clinical Scenario I: 68-yr Old Man with Early Relapse MM

Clinical Insights on Next Treatment Approach Steps

Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens 

Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM 

Overview of CAR T-cell Therapy Options in R/R MM

Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

Clinical Insights on the Patient Presentation & Treatment Course

Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM